PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide...
Hence then, the article about camurus nda resubmission for cam2029 in acromegaly accepted for review by the us fda was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA )
Also on site :
- Coca-Cola suspended production at its Fairlife dairy after a ransomware attack
- Ancient chariot emerges among remains of mysterious society that burned down its own buildings and then disappeared
- Martha Stewart's Cloud-Like Slip-on Skechers Are the Perfect Everyday Shoe, and They're 25% Off at JCPenney